Cargando…

A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study

BACKGROUND: Paediatric systemic lupus erythematosus (pSLE) exhibits an aggressive clinical phenotype with severe complications and overall poor prognosis. The aim of this study was to analyse differential expression of low molecular weight (LMW) serum protein molecules of pSLE patients with active d...

Descripción completa

Detalles Bibliográficos
Autores principales: Rana, Anita, Minz, Ranjana W, Aggarwal, Ritu, Sharma, Sadhna, Pasricha, Neelam, Anand, Shashi, Singh, Surjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551672/
https://www.ncbi.nlm.nih.gov/pubmed/22901283
http://dx.doi.org/10.1186/1546-0096-10-24
_version_ 1782256588624494592
author Rana, Anita
Minz, Ranjana W
Aggarwal, Ritu
Sharma, Sadhna
Pasricha, Neelam
Anand, Shashi
Singh, Surjit
author_facet Rana, Anita
Minz, Ranjana W
Aggarwal, Ritu
Sharma, Sadhna
Pasricha, Neelam
Anand, Shashi
Singh, Surjit
author_sort Rana, Anita
collection PubMed
description BACKGROUND: Paediatric systemic lupus erythematosus (pSLE) exhibits an aggressive clinical phenotype with severe complications and overall poor prognosis. The aim of this study was to analyse differential expression of low molecular weight (LMW) serum protein molecules of pSLE patients with active disease in comparison to sera of healthy age matched controls. Further, some of the differential expressed spots were characterised and identified by Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS) and liquid chromatography (LC-MS). METHODS: 2D-PAGE was performed using pooled sera of active pSLE and age matched healthy controls. Gels were silver-stained and differentially expressed protein spots were detected by automated image master platinum 2D software. 79 ± 17 protein spots were detected for control gels and 78 ± 17 protein spots for patient gels. Of these eleven protein spots were selected randomly and characterized by MALDI-TOF MS (five protein spots) and LC MS (six protein spots) techniques. RESULTS: Out of the 11 protein spots, 5 protein spots were significantly upregulated viz., leiomodin 2 (LMOD2); epidermal cytokeratin 2; immunoglobulin kappa light chain variable region; keratin 1 and transthyretin (TTR). Three protein spots were significantly down regulated e.g., apolipoprotein A1 (APOA1); chain B human complement component C3c; campath antibody antigen complex. Two protein spots (complement component C3; retinol binding protein (RBP) were found to be expressed only in disease and one protein spot cyclohydrolase 2 was only expressed in controls. CONCLUSIONS: We conclude that 2-D maps of patients with active pSLE and controls differ significantly. In this pilot study, using proteomic approach we have identified differential expressed proteins (of LMW) e.g., RBP, LMOD 2, TTR, Component C3c Chain B and APO A1. However, in future, further studies need to confirm the physiological and pathological role of these proteins in similar cohorts of pSLE.
format Online
Article
Text
id pubmed-3551672
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35516722013-01-24 A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study Rana, Anita Minz, Ranjana W Aggarwal, Ritu Sharma, Sadhna Pasricha, Neelam Anand, Shashi Singh, Surjit Pediatr Rheumatol Online J Research BACKGROUND: Paediatric systemic lupus erythematosus (pSLE) exhibits an aggressive clinical phenotype with severe complications and overall poor prognosis. The aim of this study was to analyse differential expression of low molecular weight (LMW) serum protein molecules of pSLE patients with active disease in comparison to sera of healthy age matched controls. Further, some of the differential expressed spots were characterised and identified by Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS) and liquid chromatography (LC-MS). METHODS: 2D-PAGE was performed using pooled sera of active pSLE and age matched healthy controls. Gels were silver-stained and differentially expressed protein spots were detected by automated image master platinum 2D software. 79 ± 17 protein spots were detected for control gels and 78 ± 17 protein spots for patient gels. Of these eleven protein spots were selected randomly and characterized by MALDI-TOF MS (five protein spots) and LC MS (six protein spots) techniques. RESULTS: Out of the 11 protein spots, 5 protein spots were significantly upregulated viz., leiomodin 2 (LMOD2); epidermal cytokeratin 2; immunoglobulin kappa light chain variable region; keratin 1 and transthyretin (TTR). Three protein spots were significantly down regulated e.g., apolipoprotein A1 (APOA1); chain B human complement component C3c; campath antibody antigen complex. Two protein spots (complement component C3; retinol binding protein (RBP) were found to be expressed only in disease and one protein spot cyclohydrolase 2 was only expressed in controls. CONCLUSIONS: We conclude that 2-D maps of patients with active pSLE and controls differ significantly. In this pilot study, using proteomic approach we have identified differential expressed proteins (of LMW) e.g., RBP, LMOD 2, TTR, Component C3c Chain B and APO A1. However, in future, further studies need to confirm the physiological and pathological role of these proteins in similar cohorts of pSLE. BioMed Central 2012-08-17 /pmc/articles/PMC3551672/ /pubmed/22901283 http://dx.doi.org/10.1186/1546-0096-10-24 Text en Copyright ©2012 Rana et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Rana, Anita
Minz, Ranjana W
Aggarwal, Ritu
Sharma, Sadhna
Pasricha, Neelam
Anand, Shashi
Singh, Surjit
A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study
title A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study
title_full A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study
title_fullStr A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study
title_full_unstemmed A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study
title_short A comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using MALDI-TOF-TOF and LC MS–A pilot study
title_sort comparative proteomic study of sera in paediatric systemic lupus erythematosus patients and in healthy controls using maldi-tof-tof and lc ms–a pilot study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551672/
https://www.ncbi.nlm.nih.gov/pubmed/22901283
http://dx.doi.org/10.1186/1546-0096-10-24
work_keys_str_mv AT ranaanita acomparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT minzranjanaw acomparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT aggarwalritu acomparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT sharmasadhna acomparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT pasrichaneelam acomparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT anandshashi acomparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT singhsurjit acomparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT ranaanita comparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT minzranjanaw comparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT aggarwalritu comparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT sharmasadhna comparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT pasrichaneelam comparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT anandshashi comparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy
AT singhsurjit comparativeproteomicstudyofserainpaediatricsystemiclupuserythematosuspatientsandinhealthycontrolsusingmalditoftofandlcmsapilotstudy